Company news
HemoGenyx Pharmaceuticals PLC news in 2024
HemoGenyx Pharmaceuticals PLC's news releases, calls and decks from 2024, newest first.
Opening of First Clinical Site
December 30, 2024
Ultrafast CAR-T Manufacturing
December 19, 2024
Admission of New Ordinary Shares and New ISIN
December 10, 2024
Result of Extraordinary General Meeting
December 9, 2024
CBR Macrophage Delivery Update
December 6, 2024
Notice of Extraordinary General Meeting
November 22, 2024
Institutional Investment
November 11, 2024
Schedule for Phase I Clinical Trial Opening
October 30, 2024
Strategic Investment from Prevail Partners, LLC
October 2, 2024
Hemogenyx Pharmaceuticals plc - Half-year Report
September 30, 2024
Half-year Report
September 27, 2024
FLT3 Assay Ready for Phase I Trials at MD Anderson
September 9, 2024
CDX Development Update
September 2, 2024
Presentation at CBD S&T Conference
August 28, 2024
Macrophage-Directed Therapies Summit Presentation
July 29, 2024
Result of Annual General Meeting
June 27, 2024
Operations Update
June 17, 2024
Posting of Annual Report & Notice of AGM
June 3, 2024
Final Results
April 25, 2024
Placing to Raise US$4.2 million
February 29, 2024
CBR Brain Delivery
February 16, 2024
CBR Intranasal Delivery
February 14, 2024
FDA Consents to Phase I Trials of HEMO-CAR-T
February 9, 2024
Approval and Issuance of U.S. Conditioning Patent
February 2, 2024
Submission of Complete Response to Clinical Hold
January 16, 2024
HEMO-CAR-T Process Qualification Run Completed
January 8, 2024
Decks in 2024
- Investor Presentation (October 2024)
Investor deck · 24 slides · October 2024